| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/22/2004 | CA2492355A1 Method for diagnosis of intestinal-type gastric tumors |
| 01/22/2004 | CA2492160A1 Mesothelin vaccines and model systems |
| 01/22/2004 | CA2492068A1 Assays for assembly of ebola virus nucleocapsids |
| 01/22/2004 | CA2491704A1 Immunogenic composition comprising a fusion protein and a saponin adjuvant |
| 01/22/2004 | CA2489410A1 Molecular antigen arrays |
| 01/21/2004 | EP1382969A1 Diagnosis and prevention of cancer cell invasion |
| 01/21/2004 | EP1382688A1 Screening method |
| 01/21/2004 | EP1382616A2 Pharmaceutical composition for use in the treatment of abnormalities associated with the activity of a human Y5-receptor |
| 01/21/2004 | EP1382348A2 Polynucleotide vaccine formula, particularly for treating bovine respiratory disease |
| 01/21/2004 | EP1382345A2 Uses of inhibitors of hemostasis |
| 01/21/2004 | EP1381839A2 Method of imaging cell death in vivo |
| 01/21/2004 | EP1381684A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/21/2004 | EP1381674A2 Method for generating highly active human dendritic cells from monocytes |
| 01/21/2004 | EP1381631A2 Human timp-1 antibodies |
| 01/21/2004 | EP1381630A2 Vhh single heavy chain antibody and a method for its preparation in a mammal |
| 01/21/2004 | EP1381628A2 Inflammation-specific peptides and the uses thereof |
| 01/21/2004 | EP1381415A1 Method of intradermally injecting substances |
| 01/21/2004 | EP1381397A2 Stabilisation of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 01/21/2004 | EP1381391A1 Vaccines including as an adjuvant type 1 ifn and processes related thereto |
| 01/21/2004 | EP1381390A2 Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen |
| 01/21/2004 | EP1381389A1 Smallpox vaccine |
| 01/21/2004 | EP1381388A1 Production of peptides in plants as n-terminal viral coat protein fusions |
| 01/21/2004 | EP1381387A2 Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases |
| 01/21/2004 | EP1381384A2 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFa |
| 01/21/2004 | EP1381381A1 Patch for transcutaneous immunization |
| 01/21/2004 | EP1381380A1 Pharmaceutical composition containing bulbophyllum |
| 01/21/2004 | EP1381346A2 Aerosol compositions containing formoterol for delivery to the lungs via nebulization |
| 01/21/2004 | EP1381345A2 Delivery of disease control in aquaculture and agriculture using microbes containing bioactive proteins |
| 01/21/2004 | EP1381344A2 Novel vaccine |
| 01/21/2004 | EP1381280A1 Viral vectors and their use in therapeutic methods |
| 01/21/2004 | EP0944397B1 Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances |
| 01/21/2004 | EP0734263B1 ALPHAvBETA3 INTEGRIN AS A PREDICTOR OF ENDOMETRIOSIS |
| 01/21/2004 | EP0667786B1 Retro-, inverso-, and retro-inverso synthetic peptide analogues |
| 01/21/2004 | CN1469926A Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/21/2004 | CN1469923A Method of extensive culture of antigen-specific cytotoxic T cells |
| 01/21/2004 | CN1469883A Peptide selection method |
| 01/21/2004 | CN1469755A Vaccines containing ribavirin and methods of use thereof |
| 01/21/2004 | CN1469746A A retroviral immunotherapy |
| 01/21/2004 | CN1468958A Synthesis and high-efficiency expression method of bivalent foot-and-mouth disease polypeptide vaccine |
| 01/21/2004 | CN1468957A Plasmid used as human therapeutic vaccine adjuvant |
| 01/21/2004 | CN1468955A New type of coronavirus |
| 01/21/2004 | CN1468633A Acne treating bacterial vaccine |
| 01/20/2004 | US6680375 Antibody for use in the diagnosis, treatment and prevention of bone disorders and cancer |
| 01/20/2004 | US6680372 Antibodies specific for growth differentiation factor-7 |
| 01/20/2004 | US6680197 Breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, and t cells that are specific for cells expressing such polypeptides. |
| 01/20/2004 | US6680195 Extracellular matrix-binding proteins from staphylococcus aureus |
| 01/20/2004 | US6680182 Promoter sequence operably linked to a dna sequence encoding first and second proteins linked by hinge regiion; tetanus toxin c fragments |
| 01/20/2004 | US6680168 Passive immunization against clostridium difficile disease |
| 01/20/2004 | US6680061 Isolated hydrophilic polypeptide inducing protection against eimeria infection in poultry |
| 01/20/2004 | US6680060 A live hepatitis a virus adapted to growth in mrc-5 cells (human fibroblast-like cell line) |
| 01/20/2004 | US6680059 Vaccines containing ribavirin and methods of use thereof |
| 01/20/2004 | US6680056 Stimulating proliferation of cytolytic t cells |
| 01/20/2004 | US6680054 Macromolecular neuraminidase-binding compounds |
| 01/20/2004 | CA2241247C Archaeosomes, archaeosomes containing coenzyme q10, and other types of liposomes containing coenzyme q10 as adjuvants and as delivery vehicles |
| 01/20/2004 | CA2101534C Monoclonal antibodies to putative hcv envelope region and methods for using same |
| 01/20/2004 | CA2090961C Specific binding agents |
| 01/20/2004 | CA2078235C Idiotypic vaccination against b cell lymphoma |
| 01/15/2004 | WO2004005530A2 Compositions and methods for treatment and detection of multiple cancers |
| 01/15/2004 | WO2004005523A1 Recombinant poxvirus not having a functional 3beta-hsd gene |
| 01/15/2004 | WO2004005512A1 Nove protein and use thereof |
| 01/15/2004 | WO2004005493A1 Animal protein free media for cultivation of cells |
| 01/15/2004 | WO2004005480A2 Plastid genetic engineering via somatic embryogenesis |
| 01/15/2004 | WO2004005476A2 Nucleic acid compositions for stimulating immune responses |
| 01/15/2004 | WO2004005473A2 Hcv fusion proteins with modified ns3 domains |
| 01/15/2004 | WO2004005465A2 Compositions and methods for the detection of human t cell receptor variable family gene expression |
| 01/15/2004 | WO2004005463A2 Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer |
| 01/15/2004 | WO2004005457A2 Tfc/ beta-catenin regulated genes for treating cancer |
| 01/15/2004 | WO2004005349A2 Preparation based on an antibody directed against a tumor-associated glycosylation such as lewis structures |
| 01/15/2004 | WO2004005325A2 Antigen-polymer compositions |
| 01/15/2004 | WO2004005316A2 Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes |
| 01/15/2004 | WO2004004767A1 Treatment of autoimmune diseases |
| 01/15/2004 | WO2004004765A1 Treatment of autoimmune skin diseases |
| 01/15/2004 | WO2004004764A1 Composition against white spot disease |
| 01/15/2004 | WO2004004763A2 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | WO2004004762A1 Iscom preparation and use thereof |
| 01/15/2004 | WO2004004761A2 Adjuvant viral particle |
| 01/15/2004 | WO2004004760A1 Vaccine for feline infectious peritonitis |
| 01/15/2004 | WO2004004759A1 Vaccine for the prevention of bacterial infection of the bovine mammary gland |
| 01/15/2004 | WO2004004758A1 Method to enhance an immune response of nucleic acid vaccination |
| 01/15/2004 | WO2004004751A1 Angio-immunotherapy |
| 01/15/2004 | WO2004004750A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | WO2004004743A1 Immunostimulation by chemically modified rna |
| 01/15/2004 | WO2004004698A2 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | WO2004004687A2 Liposomal vaccine |
| 01/15/2004 | WO2004004668A2 Immune modulatory activity of human ribonucleases |
| 01/15/2004 | WO2004004661A2 Boroproline compound combination therapy |
| 01/15/2004 | WO2004004658A2 Methods and compositions relating to isoleucine boroproline compounds |
| 01/15/2004 | WO2004004639A2 A novel stable formulation |
| 01/15/2004 | WO2004004633A2 Use of tnfalpha antibodies and another drug |
| 01/15/2004 | WO2003099868A3 Method for obtaining anti-idiotype antibodies |
| 01/15/2004 | WO2003082183A3 Protein-based streptococcus pneumoniae vaccines |
| 01/15/2004 | WO2003080800A3 Prevention and treatment of disease using angiogenesis-and/or tumor antigens |
| 01/15/2004 | WO2003077943A3 Method for the production of a pharmaceutical preparation by adsorption in a poorly soluble aluminum compound |
| 01/15/2004 | WO2003066060A3 Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| 01/15/2004 | WO2003063786A3 Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
| 01/15/2004 | WO2003059260A3 Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| 01/15/2004 | WO2003057148A3 Use of biomolecular targets in the treatment and visualization of tumors |
| 01/15/2004 | WO2003054008A3 Mammalian simp protein, gene sequence and uses thereof in cancer therapy |
| 01/15/2004 | WO2003050271A3 In vitro production of dendritic cells from cd14+ monocytes |
| 01/15/2004 | WO2003040169A3 Human monoclonal antibodies to dendritic cells |